PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence

CDK4/6 inhibitors are being used to treat a variety of human malignancies. In well-differentiated and dedifferentiated liposarcoma their clinical promise is associated with their ability to downregulate the MDM2 protein. The downregulation of MDM2 following treatment with CDK4/6 inhibitors also indu...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Mary E., Dickson, Mark A., Antonescu, Cristina, Qin, Li-Xuan, Dooley, Scott J., Barlas, Afsar, Manova, Katia, Schwartz, Gary K., Crago, Aimee M., Singer, Samuel, Koff, Andrew, Tap, William D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137027/
https://www.ncbi.nlm.nih.gov/pubmed/29789718
http://dx.doi.org/10.1038/s41388-018-0332-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137027/
https://www.ncbi.nlm.nih.gov/pubmed/29789718
http://dx.doi.org/10.1038/s41388-018-0332-y

Ejemplares similares